medigraphic.com

2012, Number 3

<< Back Next >>

Cir Cir 2012; 80 (3)

Primary prevention of cervical cancer

Vargas-Hernández VM, Acosta-Altamirano G

Language: Spanish
References: 42
Page: 291-300
PDF size: 361.45 Kb.


ABSTRACT

Cervical cancer is a global public health problem related to infection by human papilloma virus. Countries with organized programs for detection and treatment of precancerous lesions and cervical cancer prevent 80% of cases; however, prevention-based cytology, colposcopy and treatment of injuries is effective but still expensive, invasive and nonspecific, especially in developing countries. The goal of primary prevention through immunization against human papillomavirus is with the use of quadrivalent vaccine genotypes 6, 11, 16 and 18 and bivalent genotypes 16 and 18, which are produced using recombinant technology. These are effective in patients without prior exposure to viral genotypes, mainly when they have not initiated sexual activity. Recommended ages are 9 to 13 years and vaccine is administered through school health centers or community centers who promote informational campaigns and dissemination aimed at parents who request this. Screening programs for cervical cancer are limited and only oncogenic virus immunization will reduce their frequency, saving the lives of hundreds of women worldwide.


REFERENCES

  1. Vargas HVM, Vera GD, Acosta AG, Curiel VJJ. Virus del papiloma humano. En: Cáncer en la Mujer 1st ed. México: Alfil; 2011. pp. 615-636.

  2. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomized controlled trial. Lancet Oncol 2010;11:249-257.

  3. Vargas HVM, Ruiz-Moreno LA, Rivera CJ, Ortiz de la Peña CA, Cortés GME. Diagnóstico y tratamiento de la citología anormal. En: Cáncer en la mujer. 1a ed. México: Alfil; 2011. pp. 575-609.

  4. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005;32(suppl 1):S16-S24.

  5. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Res Cancer 2002;2:342–350.

  6. Muñoz N, Castellsagué X, Berrington de González A, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24(suppl 3):S1-S10.

  7. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370(9590):890-907.

  8. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621-632.

  9. Vargas HVM, Acosta AG. Vacunas para virus del papilloma humano. Enf Tract Gen Inf 2007;1:36-44.

  10. Smith JS, Melendy A, Rana RK, Pimenta JM. Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health 2008;43(suppl 4):S5-S25.

  11. Castellsagué X, Díaz M, De Sanjosé S, Muñoz N, Herrero R, Franceschi S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006;98:303–315.

  12. Heideman DAM, Snijders PJF, Berkhof J, Verheijen RHM, Helmerhorst TJM, Meijer CJLM. Vaccination against HPV: indications for women and the impact on the cervical screening programme. BJOG 2008;115:938–946.

  13. Crosbie EJ, Brabin L. Cervical cancer: problem solved? Vaccinating girls against human papillomarivus. BJOG 2010;117:137–142.

  14. Downs LS Jr, Scarinci I, Einstein MH, Collins Y, Flowers L. Overcoming the barriers to HPV vaccination in high-risk populations in the US. Gynecol Oncol 2010;117:486–490.

  15. Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC, Zanini RR. Efficacy of human papillomavirus vaccines: a systematic quantitative review. Int J Gynecol Cancer 2009;19:1166–1176.

  16. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomized study in young women. Lancet 2009;374(9686):301–314.

  17. Harper DM. Currently approved prophylactic HPV vaccines. Expert Rev Vaccines 2009;8:1663–1679.

  18. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KED, Marchant CD, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006;118:2135–2145.

  19. Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007;25:4931–4939.

  20. Garland SM, Steben M, Hernandez-Avila M, Koutsky LA, Wheeler CM, Perez G, et al. Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-ike particle accines. Clin Vaccine Immunol 2007;14:792–795.

  21. Giannini SL, Hanon E, Morris P, Van Michelin M, Morel S, Dressy F. Enhanced humoral and memory B cellular immunity using HPV16/18 L1VLP vaccine formulated with the MPL/aluminum salt combination (AS04) compared to aluminum salt only. Vaccine 2006;24:5937–5949.

  22. Stanley M, Lowy DR, Frazer I. Chapter 12: Prophylactic HPV Vaccines: Underlying mechanisms. Vaccine 2006;24(suppl 3):S106–S113.

  23. Stanley M. Potential mechanisms for HPV vaccine-induced longterm protection. Gynecol Oncol 2010;118(suppl 1):S2–S7.

  24. Villa LL. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine. Int J Infect Dis 2007;11(suppl 2):S17–S25.

  25. González-Garza C, Rojas-Martínez R, Hernández-Serrato MI, Olaiz-Fernández G. Perfil del comportamiento sexual en adolescentes mexicanos de 12 a 19 años de edad. Resultados de la ENSA 2000. Salud Publica Mex 2005;47:209–218.

  26. Kim JJ, Brisson M, Edmunds WJ, Goldie SJ. Modeling cervical cancer prevention in developed countries. Vaccine 2008;26(suppl 10):K76–K86.

  27. Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a lowresource setting. Br J Cancer 2007;97:1322–1328.

  28. Insinga RP, Dasbach EJ, Elbasha EH, Puig A, Reynales-Shigematsu LM. Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine 2007;26:128–139.

  29. Koutsky L. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915–1927.

  30. Ault KA. The Future II Study Group: effect of a prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomized clinical trials. Lancet 2007;369(9576):1861–1868.

  31. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928–1943.

  32. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, et al. Efficacy of a prophylactic adjuvant bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomized controlled trial. Lancet 2007;369(9580):2161–2170.

  33. Vargas HVM. Eficacia y seguridad de la inmunización contra la infección del papiloma virus humano. Rev Enfer Tract Genit Inf 2008;2:44.

  34. Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, Ciprero KL, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol 2009;114:1179–1188.

  35. Wacholder S, Chen BE, Wilcox A, Macones G, Gonzalez P, Befano B, et al. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomized controlled trials. BMJ 2010;340:c712.

  36. Palefsky JM, Gillison ML, Strickler HD. Chapter 16: HPV vaccines in immunocompromised women and men. Vaccine 2006;24(Supl 3):S3/140-146..

  37. Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, et al. A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions. Cancer Prev Res 2009;2:868-878.

  38. Dempsey AF, Zimet GD, Davis RL, Koutsky L. Factors That Are Associated With Parental Acceptance of Human Papillomavirus Vaccines: A Randomized Intervention Study of Written Information About HPV. Pediatrics 2006;117(5):1486-1493.

  39. Dempsey AF, Gebremariam A, Koutsky L, Manhart L. Behavior in early adolescence and risk of human papillomavirus infection as a young adult: results from a population-based study. Pediatrics 2008;122(1):1-7.

  40. Asbury K, Turner MJ. Human Papillomavirus Vaccination in the Prevention of Cervical Neoplasia. Int J Gynecol Cancer 2009;19(9):1610-1613.

  41. Konno R, Sasagawa T, Fukuda T, Van Kriekinge G, Demarteau N. Cost-Effectiveness Analysis of Prophylactic Cervical Cancer Vaccination in Japanese Women. Int J Gynecol Cancer 2010;20(3):385-392.

  42. Puig-Tintoré LM, Castellsagué X, Torné A, de Sanjosé S, Cortés J, Roura E, et al. Coverage and factors associated with cervical cancer screening: Results from the AFRODITA study, a population-based survey in Spain. J Low Genit Tract Dis 2008;12(2):82-89.




2020     |     www.medigraphic.com